Anlon Healthcare IPO Sees Strong Retail Demand, Oversubscribed 1.69 Times on Day One
Anlon Healthcare's Rs 121 crore IPO was oversubscribed 1.69 times on its first day, with retail investors showing 8.98 times subscription. The IPO, priced at Rs 86-91 per share, closes on August 29 with expected listing on September 3 on NSE SME platform. The company, specializing in pharmaceutical intermediates and APIs, saw revenue growth from Rs 66 crore to Rs 120 crore and net profit increase from Rs 9.70 crore to Rs 20.50 crore in the latest year. Anand Rathi rated the IPO as 'Subscribe - Long Term' but noted it appears fully priced at a P/E ratio of 19x.
*this image is generated using AI for illustrative purposes only.
Anlon Healthcare, a Rajkot-based pharmaceutical company, has witnessed a robust response to its Initial Public Offering (IPO) on the first day of subscription. The Rs 121 crore IPO was oversubscribed 1.69 times, with retail investors showing particularly strong interest.
Subscription Details
- Overall Subscription: 1.69 times
- Retail Investors Subscription: 8.98 times
- Grey Market Premium: 4.4% above the upper price band
IPO Specifics
- Offer Size: 1.33 crore equity shares
- Price Band: Rs 86-91 per share
- Subscription Closing: August 29
- Expected Listing: September 3 on NSE SME platform
Company Overview
Anlon Healthcare specializes in high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). The company has demonstrated strong financial performance in recent years:
| Metric | Previous Year | Latest Year |
|---|---|---|
| Revenue | Rs 66.00 crore | Rs 120.00 crore |
| Net Profit | Rs 9.70 crore | Rs 20.50 crore |
Key Highlights
- Operates over 65 commercialized products
- Filed Drug Master Files across multiple regions
- IPO proceeds to fund manufacturing expansion, debt repayment, and corporate purposes
Analyst View
Anand Rathi has rated the IPO as 'Subscribe - Long Term' while noting that it appears fully priced at a P/E ratio of 19x based on the latest earnings.
The strong first-day response, particularly from retail investors, indicates significant interest in Anlon Healthcare's public offering. However, investors should consider the company's financials, growth prospects, and the broader market conditions before making investment decisions.
20
